<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04265430</url>
  </required_header>
  <id_info>
    <org_study_id>PA14-0807</org_study_id>
    <secondary_id>NCI-2019-07862</secondary_id>
    <secondary_id>PA14-0807</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT04265430</nct_id>
  </id_info>
  <brief_title>Serial Magnetic Resonance Imaging for the Prediction of Radiation-Induced Changes in Normal Tissue of Patients With Oral Cavity or Skull Base Tumors</brief_title>
  <official_title>Serial Magnetic Resonance Imaging of Longitudinal Radiotherapy-Attributable Normal Tissue Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase IV trial studies how well serial magnetic resonance imaging (MRI) after radiation
      therapy works in predicting radiation-induced changes in the normal tissue of patients with
      oral cavity or skull base tumors. Performing MRIs after radiation therapy for patients with
      oral cavity or skull base tumors may help to predict osteoradionecrosis (a change in
      non-cancerous tissue).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Demonstrate the feasibility of serial magnetic resonance (MR) imaging biomarkers for
      assessment of early, intermediate, and late radiotherapy-attributable physiologic alteration
      of tumor and normal tissues and the kinetics thereof.

      II. Develop MR-biomarker inclusive predictive models for development of
      radiotherapy-attributable normal tissue injury.

      III. Define dose-response relationships between imaging biomarkers and subsequent
      radiation-induced effects.

      OUTLINE: Patients are assigned to 1 of 2 cohorts.

      COHORT I: Patients may receive a contrast agent intravenously (IV) and then undergo an MRI
      over 45-60 minutes at baseline, 3-5 weeks after starting standard of care radiation therapy,
      and then at 2 months, 6 months, 12 months, and 3 years after completing radiation therapy.

      COHORT II: Patients may receive a contrast agent IV and then undergo an MRI over 45-60
      minutes at baseline, and at 5-10 weeks and 12 months after standard of care surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 17, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Radiotherapy-attributable for normal tissue injury</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Will correlate whether post-therapy alterations in the observed multi-parametric imaging features can be used as surrogate bio-markers of normal tissue injury.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-response correlation between imaging biomarkers</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Penalized spline mixed regression will be used to characterize the induced functional relationships between the delivered dose and imaging biomarkers identified at each imaging time point. Doses for which 95% confidence interval estimates of mean trajectory fail to overlap will characterize ranges that yield significantly different levels of dose-dependent modulation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-response correlation between subsequent radiation-induced effects</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Penalized spline mixed regression will be used to characterize the induced functional relationships between the delivered dose and imaging biomarkers identified at each imaging time point. Doses for which 95% confidence interval estimates of mean trajectory fail to overlap will characterize ranges that yield significantly different levels of dose-dependent modulation.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">425</enrollment>
  <condition>Malignant Oral Cavity Neoplasm</condition>
  <condition>Malignant Skull Base Neoplasm</condition>
  <condition>Osteoradionecrosis</condition>
  <arm_group>
    <arm_group_label>MRI after radiation therapy (Cohort I)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients may receive a contrast agent IV and then undergo an MRI over 45-60 minutes at baseline, 3-5 weeks after starting standard of care radiation therapy, and then at 2 months, 6 months, 12 months, and 3 years after completing radiation therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MRI after surgery (Cohort II)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients may receive a contrast agent IV and then undergo an MRI over 45-60 minutes at baseline, and at 5-10 weeks and 12 months after standard of care surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Contrast Agent</intervention_name>
    <description>Given IV</description>
    <arm_group_label>MRI after radiation therapy (Cohort I)</arm_group_label>
    <arm_group_label>MRI after surgery (Cohort II)</arm_group_label>
    <other_name>Contrast</other_name>
    <other_name>Contrast Drugs</other_name>
    <other_name>contrast material</other_name>
    <other_name>Contrast Medium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Magnetic Resonance Imaging</intervention_name>
    <description>Undergo MRI</description>
    <arm_group_label>MRI after radiation therapy (Cohort I)</arm_group_label>
    <arm_group_label>MRI after surgery (Cohort II)</arm_group_label>
    <other_name>Magnetic Resonance Imaging Scan</other_name>
    <other_name>Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance</other_name>
    <other_name>MR Imaging</other_name>
    <other_name>MRI</other_name>
    <other_name>MRI Scan</other_name>
    <other_name>NMR Imaging</other_name>
    <other_name>NMRI</other_name>
    <other_name>nuclear magnetic resonance imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>MRI after radiation therapy (Cohort I)</arm_group_label>
    <arm_group_label>MRI after surgery (Cohort II)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>MRI after radiation therapy (Cohort I)</arm_group_label>
    <arm_group_label>MRI after surgery (Cohort II)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histologically proven malignant neoplasms of the oral cavity and skull
             base

          -  Patients whom, currently or previously, dispositioned to treatment with radiotherapy

          -  Patients with good performance status (Eastern Cooperative Oncology Group [ECOG] score
             0-2)

          -  Patients willing to give written informed consent

        Exclusion Criteria:

          -  Patients unable to tolerate diffusion weighted (DW)-MRI or dynamic contrast-enhanced
             (DCE)-MRI or having an estimated glomerular filtration rate (GFR) &lt; 60 ml/min/1.73m^2

          -  Patients with contraindication to MRI (e.g. non-MRI compatible metallic implants)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Y Lai</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephen Y. Lai</last_name>
    <phone>713-792-6920</phone>
    <email>sylai@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Y. Lai</last_name>
      <phone>713-792-6920</phone>
    </contact>
    <investigator>
      <last_name>Stephen Y. Lai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>December 3, 2019</study_first_submitted>
  <study_first_submitted_qc>February 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2020</study_first_posted>
  <last_update_submitted>February 10, 2020</last_update_submitted>
  <last_update_submitted_qc>February 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Skull Base Neoplasms</mesh_term>
    <mesh_term>Mouth Neoplasms</mesh_term>
    <mesh_term>Osteoradionecrosis</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

